Cargando…

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment

PURPOSE: Several adjuvant phase III trials are evaluating cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy (ET) in hormonal receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) early-stage breast cancer (eBC). This study examines pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beusterien, Kathleen, Maculaitis, Martine C, Hallissey, Bernadette, Gaschler, Michael M, Smith, Mary Lou, Law, Ernest H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987325/ https://www.ncbi.nlm.nih.gov/pubmed/33776424 http://dx.doi.org/10.2147/PPA.S298670

Ejemplares similares

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling
por: Maculaitis, Martine C, et al.
Publicado: (2020)

Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment
por: Cambron-Mellott, M Janelle, et al.
Publicado: (2021)

Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment
por: Joko, Takeshi, et al.
Publicado: (2020)

Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment
por: Dhanda, Devender S., et al.
Publicado: (2020)

Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment
por: King-Concialdi, Kristen, et al.
Publicado: (2023)

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
por: Liu, Frank Xiaoqing, et al.
Publicado: (2017)

Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians
por: Yang, Jingyan, et al.
Publicado: (2021)

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists
por: Fernández, Ovidio, et al.
Publicado: (2022)

Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment
por: Yong, Candice, et al.
Publicado: (2022)

Oncologists’ perspectives on adherence/non-adherence to adjuvant endocrine therapy and management strategies in women with breast cancer
por: Eraso, Yolanda
Publicado: (2019)

Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects
por: Le, Hannah, et al.
Publicado: (2021)

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment
por: Kumar, Jinender, et al.
Publicado: (2021)

Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment
por: WEILANDT, Juliane, et al.
Publicado: (2020)

Best Graph Type to Compare Discrete Groups: Bar, Dot, and Tally
por: Zhao, Fang, et al.
Publicado: (2021)

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
por: Livingstone, Ann, et al.
Publicado: (2023)

Patient Preferences for Longer or More Frequent In-Center Hemodialysis Regimens: A Multicenter Discrete Choice Study
por: Fotheringham, James, et al.
Publicado: (2022)

Preferences of people living with HIV for features of tuberculosis preventive treatment regimens – a discrete choice experiment
por: Aschmann, Hélène E., et al.
Publicado: (2023)

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
por: Illouz, Frédéric, et al.
Publicado: (2017)

Graph schema and best graph type to compare discrete groups: Bar, line, and pie
por: Zhao, Fang, et al.
Publicado: (2022)

Hospitals and the Tax-Payer
Publicado: (1920)

Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist’s Perspective
por: Park, Sehhoon
Publicado: (2023)

McCune-Albright Syndrome Mimicking Malignancy: an Endocrine Disease From Oncologist’s Perspective
por: Genç, D. Bahar, et al.
Publicado: (2012)

Managed care and inpatient mortality in adults: effect of primary payer
por: Hines, Anika L., et al.
Publicado: (2017)

A Private Payer Persective
por: Shurney, Dexter W.
Publicado: (2006)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Continuous controversy about radiation oncologists’ choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?
por: Nieder, Carsten, et al.
Publicado: (2013)

Current and future choices in endocrine therapy
por: Ellis, Matthew
Publicado: (2007)

Ethical Considerations for Discrete Choice Experiments with Caregivers
por: Illes, Judy, et al.
Publicado: (2022)

The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer: A STROBE-compliant retrospective cohort study
por: Yin, Luxi, et al.
Publicado: (2018)

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Factors Driving Patient Preferences for Growth Hormone Deficiency (GHD) Injection Regimen and Injection Device Features: A Discrete Choice Experiment
por: McNamara, Michelle, et al.
Publicado: (2020)

All-payer ratesetting: Down but not out
por: Anderson, Gerard F.
Publicado: (1992)

Are payers treating orphan drugs differently?
por: Cohen, Joshua P., et al.
Publicado: (2014)

Payer-Negotiated Prices for Telemedicine Services
por: Wu, Shannon S., et al.
Publicado: (2022)

An integrated valuation model for payer and investor
por: Nuijten, Mark, et al.
Publicado: (2022)

Payer Perspectives on Health Technology Assessment
por: Watkins, John B.
Publicado: (2012)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective
por: Yoo, Minkyoung, et al.
Publicado: (2023)

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
por: Attia, Yasmin M., et al.
Publicado: (2020)

The role of the oncologist
por: Rossi, M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cktruh3e63bh7k3voh7g8i9g2f